Amsterdam UMC

Running trials

• Not yet recruiting

  Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)

  NCT07799298· Source

• Not yet recruiting

  Closed-Loop Therapeutic Refinement Using Local Field Potentials in Parkinson's Disease

  NCT07105280· Source

• Not yet recruiting

  NutrImmune: Precision Nutrition to Improve Immunity in Individuals With Obesity

  NCT07850206· Source

• Recruiting

  METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

  NCT07699380· Phase 2· Source

• Not yet recruiting

  Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer

  NCT07846046· Source

• Recruiting

  Timing of Immunotherapy in Melanoma

  NCT07696715· Source

• Active, not recruiting

  A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

  2023-503298-39-00· Phase 3· Source

• Recruiting

  The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

  NCT06494878· Phase 3· Source

• Recruiting

  Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

  NCT07645625· Phase 4· Source

• Recruiting

  Effect of 4 Weeks of Oral Probiotic Desulfovibrio Piger Supplementation on Immunological and Metabolic Parameters in Individuals With Longstanding Type 1 Diabetes

  NCT07585994· Source

• Recruiting

  Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer

  NCT07632079· Phase 2· Source

• Recruiting

  Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation

  NCT07556887· Source

• Recruiting

  Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

  NCT06909045· Source

• Recruiting

  Brain Stimulation in Long COVID

  NCT07278206· Source

• Recruiting

  Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons

  NCT07231835· Source

• Recruiting

  Drug-Eluting Balloon Treatment vs. Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques

  NCT07107971· Source

• Recruiting

  Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE

  2024-514693-47-01· Phase 4· Source

• Recruiting

  Preeclampsia Intervention Netherlands

  NCT06452498· Phase 3· Source

• Recruiting

  The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease

  NCT07680335· Source

• Recruiting

  Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)

  NCT07262957· Phase 4· Source

• Not yet recruiting

  Optimizing Lymph Node Staging in Esophageal Cancer with USPIO-enhanced MRI

  2023-506952-26-01· Phase 2· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Source

• Recruiting

  Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

  NCT06950385· Phase 3· Source

• Recruiting

  SIMBA

  2024-514740-82-00· Phase 4· Source

• Not yet recruiting

  TULIP ReTrain Study

  NCT06974539· Source

• Recruiting

  The TASTY-steering Study

  NCT07258563· Source

• Recruiting

  Heart CT Imaging to Detect Early Coronary Artery Disease in First-Degree Relatives With High or Low Lipoprotein(a) Identified Through Family Screening

  NCT06995183· Source

• Recruiting

  Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3)

  NCT06939023· Source

• Recruiting

  Towards Cure Via Only Ultra-short ICB in CSCC

  NCT06823479· Phase 2· Source

• Recruiting

  Effect of Inulin Supplementation on Glycaemic Control and Immunological Parameters in Type 1 Diabetes (2024)

  NCT07050888· Source

• Recruiting

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· Phase 3· Source

• Recruiting

  Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma

  NCT06962072· Source

• Recruiting

  Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)

  NCT07782164· Source

• Recruiting

  Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease

  NCT07036328· Source

• Active, not recruiting

  European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection

  NCT06935487· Source

• Active, not recruiting

  Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)

  NCT05605899· Phase 3· Source

• Recruiting

  Adaptive Anastomosis for Anterior Resection in Sigmoid and Proximal Rectal Cancer or Premalignant Lesions

  NCT07056374· Source

• Recruiting

  FARE Trial

  2023-506594-35-00· Phase 4· Source

• Recruiting

  Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

  NCT06687876· Phase 2· Source

• Recruiting

  A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

  NCT07363044· Source

• Recruiting

  [18F]ACI-19626 PET in TDP-43 Proteinopathies

  NCT06891716· Early phase 1· Source

• Recruiting

  Endocalyx in Treatment Resistent Hypertension

  NCT06940011· Phase 2· Source

• Recruiting

  Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI

  NCT07121842· Source

• Recruiting

  Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site Infections.

  NCT06638567· Source

• Recruiting

  The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma

  NCT06355427· Phase 2/3· Source

• Recruiting

  The effect of [18F]F-FAPI PET-CT on management in patients with potentially resectable biliary tract cancers: prospective multicenter study and cost-effectivity analysis.

  2023-507938-24-00· Phase 3· Source

• Active, not recruiting

  Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)

  NCT07157605· Source

• Recruiting

  Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery

  NCT06888063· Phase 2· Source

• Not yet recruiting

  Validating Digital Biomarkers to Detect Disease Activity and Disease Progression in Multiple Sclerosis

  NCT06627465· Source

• Active, not recruiting

  nCLE-Cone-beam CT Navigation Bronchoscopy

  NCT06505642· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease9 recruiting
• Gastric and esophageal cancer7 recruiting
• Colorectal cancer6 recruiting
• Liver and biliary tract cancer6 recruiting
• High blood pressure5 recruiting
• Lung cancer5 recruiting
• Pancreatic cancer5 recruiting
• Prostate cancer5 recruiting
• Alzheimer disease4 recruiting
• Childhood cancers4 recruiting
• Crohn's disease4 recruiting
• Multiple myeloma4 recruiting
• Parkinson disease4 recruiting
• Type 2 diabetes4 recruiting
• Cervical cancer3 recruiting
• Obesity3 recruiting
• Stroke3 recruiting
• Type 1 diabetes3 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Frontotemporal dementia2 recruiting
• Glioblastoma2 recruiting
• Melanoma2 recruiting
• Multiple sclerosis2 recruiting
• Neuroendocrine tumours2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Amyloidosis1 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Hepatitis B1 recruiting
• Hodgkin lymphoma1 recruiting
• Kidney cancer1 recruiting
• Long COVID and ME/CFS1 recruiting
• Ovarian cancer1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Sickle cell disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide

  NCT07819227· Phase 2· Source

• Completed

  The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris

  NCT06415227· Phase 2· Source

• Recruiting

  Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

  NCT06457789· Phase 2/3· Source

• Completed

  ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) study: safety, toxicity and immunological effects of peritumorally delivered immunotherapy in early-stage cervical cancer

  NCT06095674· Phase 1· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Source

• Completed

  Optimizing reversal of HIV latency with combination therapy (pyrimethamine, lenalidomide, panobinostat)

  NCT06240520· Phase 2· Source

• Completed

  A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

  NCT05865886· Phase 2· Source

• Completed

  MyDiaMate For Remission Of Diabetes Distress In Type 1 Diabetes (MyREMEDY)

  NCT06308549· Source

• Completed

  Unravelling intestinal fibrosis in ulcerative colitis: INTERACT study

  2023-507907-73-00· Phase 4· Source

• Completed

  Lumeneye Rectoscope for Assessment on Tumor Response After Total Neoadjuvant Treatment in Rectal Cancer

  NCT06189846· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Completed

  A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma

  NCT06018129· Phase 1/2· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma

  2022-502984-39-00· Phase 3· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

  NCT05784246· Phase 3· Source

• Completed

  Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer

  NCT05724602· Phase 2· Source

• Completed

  A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cells (GLPG5301; BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (RRMM)

  2022-500782-27-00· Phase 1/2· Source

• Completed

  A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

  NCT05952869· Phase 3· Source

• Completed

  A Trial to Evaluate Safety, Feasibility and Efficacy of Endoscopic Duodenal PEF Therapy

  NCT05984238· Source

• Completed

  Rhythmic Estradiol and Bone Health

  NCT05903820· Phase 4· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Source

• Completed

  The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy

  NCT06396403· Source

• Completed

  The Effectiveness of Adding Braun Anastomosis to Standard Child Reconstruction After Pancreatoduodenectomy

  NCT05709197· Source

• Active, not recruiting

  A Rollover Study of CC-122

  NCT05688475· Phase 1· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Source

• Completed

  Objective Neurocognitive Assessment of Young Children With Sickle Cell Disease by Eye-Tracking

  NCT07721155· Source

• Completed

  Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String

  NCT05874934· Source

• Completed

  Safety and Tolerability of AC01 in patients with heart failure

  2022-500347-20-00· Phase 1/2· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

  NCT05673057· Phase 1· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Source

• Completed

  First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)

  2023-508357-58-00· Phase 1/2· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and Confirmatory Study of AV-101 in Patients with PAH

  NCT05036135· Phase 2/3· Source

• Completed

  Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

  NCT05232071· Phase 2· Source

• Completed

  A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

  NCT04912869· Phase 1· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

  NCT05248646· Phase 3· Source

• Terminated

  Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

  NCT04186247· Phase 2· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

  NCT04793958· Phase 3· Source

• Completed

  A Phase 3 Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn's Disease.

  NCT04701411· Phase 3· Source

• Completed

  Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)

  NCT04437303· Phase 4· Source

• Completed

  COVID-19 Infection and Multiple Myeloma

  NCT04492371· Source

• Completed

  Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

  NCT04236609· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Source

• Completed

  Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN)

  2024-516581-11-00· Phase 3· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· Source

• Completed

  Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC

  NCT03834493· Phase 3· Source

• Active, not recruiting

  A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other Luspatercept (ACE-536) clinical trials.

  2022-502498-40-00· Phase 3· Source

• Completed

  Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy

  NCT04657120· Source